| Bioactivity | DYRKi is an inhibitor of DYRK1 and DYRK1B with IC50 values of 3.7 µM and 90 nM, respectively, which is used as a potent antagonist of Hh/Gli signaling. DYRKi impairs SMO-dependent and SMO-independent oncogenic GLI activity in human medulloblastoma cells. DYRKi is promising for research of HH/GLI-associated cancers[1]. |
| CAS | 1640364-04-0 |
| Formula | C20H13F3N4O2S |
| Molar Mass | 430.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kokkorakis N, et al. Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy. Pharmaceutics. 2024 Apr 11;16(4):528. [2]. Gruber W, et al. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance. Oncotarget. 2016 Feb 9;7(6):7134-48. |